Yu Hongtao, Greasley Peter, Lambers-Heerspink Hiddo, Boulton David W, Hamrén Bengt, Hallow K Melissa
Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, United States.
Early Clinical Development, Research, and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceutical R&D, AstraZeneca, Gothenburg, Sweden.
Front Pharmacol. 2024 Apr 5;15:1332394. doi: 10.3389/fphar.2024.1332394. eCollection 2024.
Endothelin-1 (ET-1) is a potent vasoconstrictor with strong anti-natriuretic and anti-diuretic effects. While many experimental studies have elucidated the mechanisms of ET-1 through its two receptors, ET and ET, the complexity of responses and sometimes conflicting data make it challenging to understand the effects of ET-1, as well as potential therapeutic antagonism of ET-1 receptors, on human physiology. In this study, we aimed to develop an integrated and quantitative description of ET-1 effects on cardiovascular and renal function in healthy humans by coupling existing experimental data with a mathematical model of ET-1 kinetics and an existing mathematical model of cardiorenal function. Using a novel agnostic and iterative approach to incorporating and testing potential mechanisms, we identified a minimal set of physiological actions of endothelin-1 through ET and ET receptors by fitting the physiological responses (changes in blood pressure, renal blood flow, glomerular filtration rate (GFR), and sodium/water excretion) to ET-1 infusion, with and without ET/ET antagonism. The identified mechanisms align with previous experimental studies on ET-1 and offer novel insights into the relative magnitude and significance of endothelin's effects. This model serves as a foundation for further investigating the mechanisms of ET-1 and its antagonists.
内皮素 -1(ET-1)是一种强效血管收缩剂,具有强大的抗利钠和抗利尿作用。虽然许多实验研究已经通过其两种受体ET_A和ET_B阐明了ET-1的作用机制,但反应的复杂性以及有时相互矛盾的数据使得理解ET-1对人体生理学的影响以及ET-1受体潜在的治疗性拮抗作用具有挑战性。在本研究中,我们旨在通过将现有的实验数据与ET-1动力学数学模型和现有的心肾功能数学模型相结合,对健康人体中ET-1对心血管和肾功能的影响进行综合定量描述。通过使用一种新颖的不可知论和迭代方法来纳入和测试潜在机制,我们通过将生理反应(血压、肾血流量、肾小球滤过率(GFR)和钠/水排泄的变化)与ET-1输注(有无ET_A/ET_B拮抗)进行拟合,确定了内皮素-1通过ET_A和ET_B受体产生的一组最小生理作用。所确定的机制与先前关于ET-1的实验研究一致,并为内皮素作用的相对大小和意义提供了新的见解。该模型为进一步研究ET-1及其拮抗剂的机制奠定了基础。